Related Experiment Video
Updated: Sep 26, 2025

09:12
A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
Published on: February 3, 2023
2.7K
Systemic cytokine profiles in biliary atresia
Wanvisa Udomsinprasert1, Tachatra Ungsudechachai1, Paisarn Vejchapipat2
1Department of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
Plos One
|April 22, 2022
Summary
This study identifies specific cytokine profiles associated with biliary atresia (BA) and its outcomes. Interleukin-8 (IL-8) shows potential as a diagnostic and prognostic biomarker for BA.
Area of Science:
- Immunology
- Hepatology
- Biomarker Discovery
Background:
- Biliary atresia (BA) causes pediatric liver injury due to inflammation and immune dysregulation.
- Lack of specific biomarkers hinders early diagnosis and treatment for BA.
- Identifying reliable biomarkers is crucial for pediatric liver transplantation decisions.
Purpose of the Study:
- To investigate associations between systemic cytokine profiles and clinical parameters in BA patients.
- To identify potential diagnostic and prognostic biomarkers for BA.
- To understand the role of immune responses in BA pathogenesis.
Main Methods:
- Multiplex immunoassay to measure 27 systemic cytokines in 82 BA patients and 25 controls.
- Quantitative real-time PCR to assess relative mRNA expression of candidate cytokines in BA liver tissue.
- Correlation analysis between cytokine levels and clinical parameters (jaundice, fibrosis, portal hypertension).
Main Results:
- 17 cytokines were elevated and 2 were decreased in BA patients compared to controls.
- Elevated IL-7, eotaxin, IP-10, and IL-13 correlated with unfavorable BA outcomes like jaundice and fibrosis.
- IL-8, IP-10, MCP-1, and PDGF showed potential as BA biomarkers, with IL-8 linked to reduced survival.
Conclusions:
- Systemic cytokine profiles reflect inflammatory and immune responses in BA.
- Plasma IL-8 demonstrates significant potential as a diagnostic and prognostic biomarker for BA.
- Further research into IL-8 could improve BA management and patient outcomes.

